Annals of Clinical and Translational Neurology (Jun 2021)

Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort

  • Christian Rummey,
  • John M. Flynn,
  • Louise A. Corben,
  • Martin B. Delatycki,
  • George Wilmot,
  • Sub H. Subramony,
  • Khalaf Bushara,
  • Antoine Duquette,
  • Christopher M. Gomez,
  • J. Chad Hoyle,
  • Richard Roxburgh,
  • Lauren Seeberger,
  • Grace Yoon,
  • Katherine D. Mathews,
  • Theresa Zesiewicz,
  • Susan Perlman,
  • David R. Lynch

DOI
https://doi.org/10.1002/acn3.51352
Journal volume & issue
Vol. 8, no. 6
pp. 1239 – 1250

Abstract

Read online

Abstract Objective The objective of this study was to characterize the incidence and progression of scoliosis in the natural history of Friedreich’s ataxia (FRDA) and document the factors leading to the requirement for corrective surgery. Methods Data on the prevalence of scoliosis and scoliosis surgery from up to 17 years of follow‐up collected during a large natural history study in FRDA (1116 patients at 4928 visits) were summarized descriptively and subjected to time to event analyses. Results Well over 90% of early or typical FRDA patients (as determined by age of onset) developed intermediate to severe scoliosis, while patients with a later onset (>14 years) had no or much lower prevalence of scoliosis. Diagnosis of scoliosis occurs during the onset of ataxia and in rare cases even prior to that. Major progression follows throughout the growth phase and puberty, leading to the need for surgical intervention in more than 50% of individuals in the most severe subgroup. The youngest patients appear to delay surgery until the end of the growth period, leading to further progression before surgical intervention. Age of onset of FRDA before or after reaching 15 years sharply separated severe and relatively mild incidence and progression of scoliosis. Interpretation Scoliosis is an important comorbidity of FRDA. Our comprehensive documentation of scoliosis progression in this natural history study provides a baseline for comparison as novel treatments become available.